These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 4630482)

  • 1. The structure-activity relationship of 4-(5'-nitrofurfurylidene-amino)-tetrahydro-4H-1,4-thiazine-1,1-dioxides active against Trypanosoma cruzi.
    Bock M; Haberkorn A; Herlinger H; Mayer KH; Petersen S
    Arzneimittelforschung; 1972 Sep; 22(9):1564-9. PubMed ID: 4630482
    [No Abstract]   [Full Text] [Related]  

  • 2. Animal experimental investigation into the activity of nifurtimox against Trypanosoma cruzi.
    Haberkorn A; Gönnert R
    Arzneimittelforschung; 1972 Sep; 22(9):1570-82. PubMed ID: 4630483
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: Treatment of leishmaniasis with a nitrofurfurylidene derivative (Bay 2502).
    Restrepo M; Velasquez JP
    Trans R Soc Trop Med Hyg; 1973; 67(4):616. PubMed ID: 4594462
    [No Abstract]   [Full Text] [Related]  

  • 4. Nifurtimox: causal treatment of Chagas' disease.
    Gönnert R
    Arzneimittelforschung; 1972 Sep; 22(9):1563. PubMed ID: 4630481
    [No Abstract]   [Full Text] [Related]  

  • 5. [Combined treatment of Chagas' disease with Bayer 2502 and corticoid (experimental and clinical study)].
    Andrade SG; Macêdo V
    Rev Inst Med Trop Sao Paulo; 1973; 15(6):421-30. PubMed ID: 4209018
    [No Abstract]   [Full Text] [Related]  

  • 6. Experience with nifurtimox in chronic Chagas' infection. Preliminary report.
    Wegner DH; Rohwedder RW
    Arzneimittelforschung; 1972 Sep; 22(9):1635-41. PubMed ID: 4630486
    [No Abstract]   [Full Text] [Related]  

  • 7. [Light- and electronmicroscopic studies on mastigote and amastigote stages of Trypanosoma cruzi under the influence of Lampit (author's transl)].
    Voigt WH; Haberkorn A; Gönnert R
    Z Parasitenkd; 1973 Jul; 41(4):255-67. PubMed ID: 4355120
    [No Abstract]   [Full Text] [Related]  

  • 8. [(Effect of Lampit on experimental Trypanosoma cruzi infection in mice)].
    Apt W; Mancilla R; Díaz M; Díaz S
    Bol Chil Parasitol; 1972; 27(3):80-6. PubMed ID: 4196829
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of nifurtimox in acute Chagas' infection.
    Wegner DH; Rohwedder RW
    Arzneimittelforschung; 1972 Sep; 22(9):1624-35. PubMed ID: 4630485
    [No Abstract]   [Full Text] [Related]  

  • 10. [Reaction of the Trypanosoma cruzi strain to the experimental therapeutical response to Bay 2502 (results of long term treatment)].
    Andrade SG; Figueira RM; Carvalho ML; Gorini DF
    Rev Inst Med Trop Sao Paulo; 1975; 17(6):380-9. PubMed ID: 815983
    [No Abstract]   [Full Text] [Related]  

  • 11. Ultrastructural observations on the activity of nifurtimox on the causative organism of Chagas' disease. I. Trypanosoma cruzi in tissue cultures.
    Voigt WH; Bock M; Gönnert R
    Arzneimittelforschung; 1972 Sep; 22(9):1586-9. PubMed ID: 4567081
    [No Abstract]   [Full Text] [Related]  

  • 12. Acetylene compounds of potential pharmacological value. XL. N-(tert-aminoalkynyl)-substituted 3-isothiazolidinone-1,1-dioxides and tetrahydro-1,2-thiazin-3-one-1,1-dioxides.
    Lindeke B; Dahlbom R; Ringdahl B
    Acta Pharm Suec; 1987; 24(4):161-8. PubMed ID: 3439465
    [No Abstract]   [Full Text] [Related]  

  • 13. 5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
    Cabrera E; Murguiondo MG; Arias MG; Arredondo C; Pintos C; Aguirre G; Fernández M; Basmadjián Y; Rosa R; Pacheco JP; Raymondo S; Di Maio R; González M; Cerecetto H
    Eur J Med Chem; 2009 Oct; 44(10):3909-14. PubMed ID: 19446929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of nifurtimox on Trypanosoma cruzi in tissue cultures.
    Gönnert R; Bock M
    Arzneimittelforschung; 1972 Sep; 22(9):1582-6. PubMed ID: 4567080
    [No Abstract]   [Full Text] [Related]  

  • 15. [Etiological treatment of Chagas' disease].
    Rassi A
    Arq Bras Cardiol; 1982 Apr; 38(4):277-81. PubMed ID: 6820273
    [No Abstract]   [Full Text] [Related]  

  • 16. [Etiologic therapy of Chagas' disease].
    Boainain E; Rassi A
    Arq Bras Cardiol; 1979 Jun; 32(6):395-9. PubMed ID: 116629
    [No Abstract]   [Full Text] [Related]  

  • 17. Trypanosoma cruzi: nifurtimox's effect on infectivity.
    Cardoni RL; Rimoldi MT; de Bracco MM
    Exp Parasitol; 1977 Dec; 43(2):370-5. PubMed ID: 413732
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of Chagas' disease].
    Apt W
    Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
    [No Abstract]   [Full Text] [Related]  

  • 19. Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
    Palace-Berl F; Pasqualoto KF; Jorge SD; Zingales B; Zorzi RR; Silva MN; Ferreira AK; de Azevedo RA; Teixeira SF; Tavares LC
    Eur J Med Chem; 2015; 96():330-9. PubMed ID: 25899337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of chronic Chagas' infection with Lampit].
    Schenone H; Concha L; Aranda R; Rojas A; Knierim F; Rojo M
    Bol Chil Parasitol; 1972; 27(1):11-4. PubMed ID: 4628949
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.